Abstract
Introduction
The natural history of metastatic melanoma involving lymph nodes, in the absence of a known primary site (cutaneous, ocular or mucosal) has, to date, been poorly defined; and the optimal management of this rare subtype of disease is therefore unclear. Melanomas of unknown primary site (MUP) are estimated to comprise between 3.7 and 6% of all melanomas (Anbari et al. in Cancer 79:1861–1821, 1997).
Materials and methods
Between 2002 and 2007, 478 patients were treated for melanoma in our department in Cork University Hospital, five of whom presented with MUP. We discuss their cases herein.
Conclusion
We should continue to treat this cohort of patients with an aggressive surgical approach and consider them for adjuvant therapies currently used to treat stage III disease.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Anbari KK, Schuchter LM, Bucky LP et al (1997) Melanoma of unknown primary site: presentation, treatment, and prognosis—a single institution study. University of Pennsylvania Pigmented Lesion Study Group. Cancer 79:1816–1821
Katz KA, Jonasch E, Hodi FS et al (2005) Melanoma of unknown primary: experience at Massachusetts General Hospital and Dana-Farber Cancer Institute. Melanoma Res 15:77–82
Balch CM, Buzaid AC, Soong SJ et al (2001) Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J Clin Oncol 19:3635–3648
Yee VS, Thompson JF, McKinnon JG et al (2005) Outcome in 846 cutaneous melanoma patients from a single center after a negative sentinel node biopsy. Ann Surg Oncol 12:429–439
Schlagenhauff B, Stroebel W, Ellwanger U et al (1997) Metastatic melanoma of unknown primary origin shows prognostic similarities to regional metastatic melanoma: recommendations for initial staging examinations. Cancer 80:60–65
Ho Shon IA, Chung DK, Saw RP, Thompson JF (2008) Imaging in cutaneous melanoma. Nucl Med Commun 29:847–876
Horn J, Lock-Andersen J, Sjostrand H, Loft A (2006) Routine use of FDG-PET scans in melanoma patients with positive sentinel node biopsy. Eur J Nucl Med Mol Imaging 33:887–892
Eigtved A, Andersson AP, Dahlstrom K et al (2000) Use of fluorine-18 fluorodeoxyglucose positron emission tomography in the detection of silent metastases from malignant melanoma. Eur J Nucl Med 27:70–75
Jadvar H, Johnson DL, Segall GM (2000) The effect of fluorine-18 fluorodeoxyglucose positron emission tomography on the management of cutaneous malignant melanoma. Clin Nucl Med 25:48–51
Kelly J, Leader M, Broe P (2007) Primary malignant melanoma of the oesophagus: a case report. J Med Case Rep 1:50
Kenney B, Dotto J, Homer R, Shafi N, Davydova L (2007) Primary malignant melanoma of the transverse colon: report of a case and review of the literature. Int J Surg Pathol 15:401–407
Ooi BS, Eu KW, Seow-Choen F (2001) Primary anorectal malignant melanoma: clinical features and results of surgical therapy in Singapore—a case series. Ann Acad Med Singap 30:203–205
Kirkwood JM, Ibrahim JG, Sondak VK et al (2000) High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol 18:2444–2458
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kelly, J., Redmond, H.P. Melanoma of unknown origin: a case series. Ir J Med Sci 179, 629–632 (2010). https://doi.org/10.1007/s11845-009-0405-6
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11845-009-0405-6